4,4-二氯-1-(吗啉-4-基)丁-3-烯-1,2-二酮 | 85839-49-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4,4-二氯-1-(吗啉-4-基)丁-3-烯-1,2-二酮
• 英文名称: 4,4-dichloro-1-(morpholin-4-yl)but-3-ene-1,2-dione
• 英文别名: 5,5-Dichloro-1-morpholin-4-yl-pent-4-ene-1,3-dione；5,5-Dichloro-1-morpholinopent-4-ene-1,3-dione；5,5-dichloro-1-morpholin-4-ylpent-4-ene-1,3-dione
• CAS: 85839-49-2
• 化学式: C₉H₁₁Cl₂NO₃
• 分子量: 252.097
• InChiKey: RJOYRCBHAJQXJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,4-二氯-1-(吗啉-4-基)丁-3-烯-1,2-二酮 在 高氯酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以75%的产率得到4H-吡喃-4-酮,2-氯-6-(4-吗啉基)-
  参考文献：
  名称：

  ATM inhibitors

  摘要：

  该应用涉及一种具有以下式I的化合物：其中P和Q中的一个是O，另一个是CH，Q和P中的CH之一之间存在双键，并且带有R3基团的碳原子；Y可以是O或S；R1和R2独立地是氢、可选择地取代的C1-7烷基、C3-20杂环基团或C5-20芳基，或者可以一起形成具有4至8个环原子的可选择地取代的杂环环；R3是苯基或吡啶基团，通过第一桥基团连接到一个可选择地取代的C5-20碳芳基团，该苯基或吡啶基团和可选择地取代的C5-20碳芳基团可以进一步通过第二桥基团连接，从而形成一个可选择地取代的C5-7环，苯基或吡啶基团可以进一步选择性地取代。

  公开号：

  US20040002492A1
• 作为产物：
  描述：

  Bis(2,2-dichlor-vinyl)keton 在 水 作用下， 生成 4,4-二氯-1-(吗啉-4-基)丁-3-烯-1,2-二酮
  参考文献：
  名称：

  2,4,6-三（二烷基氨基）吡啶鎓盐及相关体系，合成与反应行为

  摘要：

  2,4,6-三（二烷基氨基）吡喃鎓盐和2,6-二（二烷基氨基）-2H-吡喃-4-酮以及它们的硫代类似物，已制备了通过启动1,1,5-多步途径，5-四氯戊-1,4-二烯-3-酮（）。（二烷基氨基） -取代的三，经历亲电取代。它们可以更好地表示为类似聚次甲基的系统。2,6-双（二烷基氨基）-取代的，在羰基氧上显示出显着增加的供体反应性。

  DOI：

  10.1016/s0040-4039(00)80583-3

文献信息

• [EN] AMINOPYRONES AND THEIR USE AS ATM INHIBITORS<br/>[FR] AMINOPYRONES ET LEUR UTILISATION EN TANT QU'INHIBITEURS D'ATM
  申请人：KUDOS PHARM LTD

  公开号：WO2005016919A1

  公开（公告）日：2005-02-24

  Compounds of formula (I) wherein R1 and R2 together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring, X is S, NR’’ or CH2, R and R’ are hydrogen or specified substituents, and R’’ is a specified substituent, are useful as inhibitors of the kinase ATM (ataxia-telangiectasia mutated), particularly in the treatment of cancer and retroviral mediated diseases.

  具有式（I）的化合物，其中R1和R2与它们连接的氮原子一起形成一个可选择取代的杂环环，X为S、NR’’或CH2，R和R’为氢或指定的取代基，R’’为一个指定的取代基，可用作激酶ATM（共济失调-毛细血管扩张性疾病突变）的抑制剂，特别是在癌症和逆转录病原体介导的疾病的治疗中。
• [EN] DNA-PK INHIBITORS<br/>[FR] INHIBITEURS D'ADN-PK
  申请人：CANCER REC TECH LTD

  公开号：WO2003024949A1

  公开（公告）日：2003-03-27

  The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R?1 and R2¿ are independently hydrogen, an optionally substituted C¿1-7? alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR?4¿ and O, O and CR'4 and NR'4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R?3 and R4 or R'4¿ is an optionally substituted C¿3-20? heteroaryl or C5-20 aryl group, and the other of R?3 and R4 or R'4¿ is H, or R?3 and R4 or R'4¿ together are -A-B-, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.

  本发明涉及使用式(I)化合物及其异构体、盐、溶剂合物、化学保护形式和前药，在制备用于抑制DNA-PK活性的药物中使用，其中R?1和R2¿分别为氢、可选取代的C¿1-7?烷基、C3-20杂环基或C5-20芳基，或者可以与它们连接的氮原子一起形成具有4到8个环原子的可选取代杂环环；X和Y从CR?4¿和O、O和CR'4和NR'4和N中选取，其中不饱和度在环中适当位置，其中R?3和R4或R'4¿中的一个为可选取代的C¿3-20?杂芳基或C5-20芳基，而另一个为H，或者R?3和R4或R'4¿一起是-A-B-，它们共同代表一个融合的可选取代芳香环。这些化合物还比PI 3-激酶和/或ATM选择性地抑制DNA-PK活性。
• Dna-pk inhibitors
  申请人：——

  公开号：US20040192687A1

  公开（公告）日：2004-09-30

  The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R 1 and R 2 are independently hydrogen, an optionally substituted C 1-7 alkyl group, C 3-20 heterocyclyl group, or C 5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR 4 and O, O and CR′ 4 and NR″ 4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R 3 and R 4 or R′ 4 is an optionally substituted C 3-20 heteroaryl or C 5-20 aryl group, and the other of R 3 and R 4 or R′ 4 is H, or R 3 and R 4 or R″ 4 together are —A—B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM. 1

  本发明涉及使用式(I)化合物及其异构体、盐、溶剂合物、化学保护形式及其前药，在制备抑制DNA-PK活性的药物方面使用。其中，R1和R2分别为氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基，或者与它们连接的氮原子一起形成含有4到8个环原子的可选取代杂环环；X和Y从CR4和O、O和CR'4以及NR"4和N中选择，其中不饱和度在环中适当位置，且R3和R4或R'4中的一个为可选取代的C3-20杂芳基或C5-20芳基，而另一个为氢，或者R3和R4或R"4一起为-A-B-，它们共同表示一个融合的可选取代芳香环。这些化合物与PI 3-激酶和/或ATM相比，也具有选择性抑制DNA-PK活性的作用。
• DNA-PK INHIBITORS
  申请人：Martin Morrison Barr Niall

  公开号：US20070238729A1

  公开（公告）日：2007-10-11

  The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R 1 and R 2 are independently hydrogen, an optionally substituted C 1-7 alkyl group, C 3-20 heterocyclyl group, or C 5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR 4 and O, O and CR′ 4 and NR″ 4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R 3 and R 4 or R′ 4 is an optionally substituted C 3-20 heteroaryl or C 5-20 aryl group, and the other of R 3 and R 4 or R′ 4 is H, or R 3 and R 4 or R″ 4 together are -A-B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.

  本发明涉及使用式(I)的化合物及其异构体、盐、溶剂合物、化学保护形式和前药，在制备抑制DNA-PK活性的药物方面有用。其中，R1和R2独立地表示氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基，或者与它们连接的氮原子一起形成可选取代的含有4到8个环原子的杂环环；X和Y选自CR4和O，O和CR'4以及NR"4和N，其中不饱和度在环中适当位置，其中R3和R4或R'4中的一个为可选取代的C3-20杂芳基或C5-20芳基，而另一个为H，或者R3和R4或R"4在一起为-A-B-，代表一种融合的可选取代芳香环。这些化合物与PI 3-激酶和/或ATM相比，具有选择性地抑制DNA-PK的活性。
• ATM INHIBITORS
  申请人：Smith Graeme Cameron Murray

  公开号：US20090043091A1

  公开（公告）日：2009-02-12

  A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R 1 and R 2 together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and R N1 is selected from hydrogen, an optionally substituted C 1-7 alkyl group, an optionally substituted C 3-20 heterocyclyl group, an optionally substituted C 5-20 aryl group, an acyl group, an ester group and an amido group, and its use as a pharmaceutical.

  化合物I的化学式为：其异构体，盐，溶剂合物，化学保护形式和前药，其中：R1和R2与它们附着的氮原子一起形成一个可选取代的杂环，该杂环具有4到8个环原子；RN1选自氢，可选取代的C1-7烷基，可选取代的C3-20杂环基，可选取代的C5-20芳基，酰基，酯基和酰胺基，并用作制药用途。